Madrigal Pharmaceuticals
MDGL
208 hedge funds and large institutions have $3.43B invested in Madrigal Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 88 increasing their positions, 58 reducing their positions, and 47 closing their positions.
69% more call options, than puts
Call options by funds: $440M | Put options by funds: $260M
52% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 58
4.73% more ownership
Funds ownership: 76.45% → 81.18% (+4.7%)
2% more capital invested
Capital invested by funds: $3.36B → $3.43B (+$70M)
7% less funds holding
Funds holding: 223 → 208 (-15)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
28% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 47
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$300M |
| 2 |
PC
Paulson & Co
New York
|
+$94.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$94.1M |
| 4 |
O
OrbiMed
New York
|
+$87.1M |
| 5 |
RI
RTW Investments
New York
|
+$60M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$94.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$43.5M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$41M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$40.3M |
| 5 |
AC
Armistice Capital
New York
|
-$37.9M |
MDGL Hedge Fund Activity: Q2 2023 in Review
208 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2023, worth a combined $3.43B — up 2.1% from $3.36B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of MDGL and 34 opened new positions — a net loss of 13 holders — while 58 trimmed existing stakes and 88 added.
The largest buyer was Janus Henderson Group, adding an estimated $300M. The largest seller was Perceptive Advisors, cutting an estimated $94.1M.
- 208 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2023, down from 223 in Q1 2023.
- Funds reported $3.43B of Madrigal Pharmaceuticals stock for Q2 2023, up 2.1% quarter-over-quarter.
- 34 funds opened new Madrigal Pharmaceuticals positions in Q2 2023 and 47 closed out, a net change of -13 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2023 was Janus Henderson Group, an estimated $300M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $94.1M sold.
Based on aggregated 13F filings for Q2 2023.